The Difference Between Panitumumab and Cetuximab

Panitumumab is a fully human monoclonal antibody, while cetuximab is a chimeric monoclonal antibody with approximately 30% mouse protein that targets the ligand-binding domain of EGFR. Both antibodies inhibit the downstream signaling pathways MAPK and PI3K by binding to the extracellular domain. In metastatic colorectal cancer (mCRC), panitumumab is generally considered ineffective after progression on cetuximab treatment.

Although these two drugs have never been directly compared in randomized clinical trials, they produce similar response rates when used alone and in combination with cytotoxic drugs. Only a few studies have been published focusing on the safety and clinical efficacy of panitumumab after disease progression after treatment with cetuximab and irinotecan.32 patients with wild-type KRAS metastatic colorectal cancer who were subsequently treated with panitumumab monotherapy after progression reported an objective response rate of 22% with panitumumab, also noted among 11 evaluable patients after 8 weeks of treatment, 27% experienced mild radiation reactions and 27% of other patients experienced stable disease. Panitumumab was well tolerated in all studies. The rate of severe allergic reactions was slightly increased with cetuximab (3%) compared with panitumumab (1%).

It is understood that the original version of panitumumab has not yet been launched in China, and therefore it has not been covered by medical insurance. The price of the Hong Kong original version of panitumumab sold in Hong Kong, China100mg/5mL may be around RMB 9,000 (the price may fluctuate due to exchange rates). There are currently no generic drugs of Panitumumab on the market. If a patient has a need to purchase Panitumumab, please consult a medical consultant for specific prices and more drug information.